研究单位:[1]Fujian Cancer Hospital,Fuzhou,Fujian,China,350000[2]Hunan Cancer Hospital[3]Wuhan TongJi Hospital
研究目的:
To evaluates the effectiveness and safety of Surufatinib combined with Serplulimab plus chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Surufatinib combined with Serplulimab